The company now expects full-year revenue of $87 million to $93 million, down from its previous forecast of $95 million to $100 million. Analysts polled by FactSet had expected $96.2 million.

Chief Executive Stephen Silvestro said contracted revenue for the current year remained below prior-year levels, prompting the outlook revision. He said the company was encouraged by growth in contracted revenue for 2027, which he described as signaling a strong start to the request-for-proposals season.

Third-quarter profit rose to $1.2 million, or 6 cents a share, from about $779,000, or 4 cents a share, a year earlier. Adjusted earnings, excluding certain one-time items, were 20 cents a share, topping analysts’ estimate of 16 cents.

Revenue fell to $21.6 million from $26.1 million a year earlier, but exceeded the $21.2 million analysts had expected. OptimizeRx shares closed Wednesday down 4.3% at $8.95 and were down 27% year to date.